TY  - JOUR
JF  - AMERICAN JOURNAL OF HEMATOLOGY
UR  - https://doi.org/10.1002/ajh.27565
ID  - publicatio35431
A1  -  Salmanton-García Jon
A1  -  Marchesi Francesco
A1  -  Navrátil Milan
A1  -  Piukovics Klára
A1  -  Del Principe Maria Ilaria
A1  -  Criscuolo Marianna
A1  -  Bilgin Yavuz M
A1  -  Fracchiolla Nicola S
A1  -  Vena Antonio
A1  -  Romano Alessandra
A1  -  Falces-Romero Iker
A1  -  Sgherza Nicola
A1  -  Heras-Fernando Inmaculada
A1  -  Biernat Monika M
A1  -  Petzer Verena
A1  -  ?ák Pavel
A1  -  Weinbergerová Barbora
A1  -  Samarkos Michail
A1  -  Erben Nurettin
A1  -  van Praet Jens
A1  -  López-García Alberto
A1  -  Labrador Jorge
A1  -  Lahmer Tobias
A1  -  Drgo?a ?ubo?
A1  -  Merelli Maria
A1  -  Cuccaro Annarosa
A1  -  Martín-Pérez Sonia
A1  -  Dávila-Valls Julio
A1  -  Farina Francesca
A1  -  Cattaneo Chiara
SN  - 0361-8609
AV  - public
N2  - Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS-CoV-2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.
Y1  - 2024///
TI  - Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024 : EPICOVIDEHA-EPIFLUEHA Report
ER  -